Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) have won £113.7 million to support groundbreaking medical research.

Several images showing the breadth of research at NDORMS.

The Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) is leading two of the themes of the new NIHR Oxford Biomedical Research Centre (BRC), in Musculoskeletal sciences (Professor Andrew Carr) and Gastroenterology & Mucosal Immunity (Professor Fiona Powrie).

The National Institute for Health Research (NIHR), which is funded through the Department for Health, today announced that the Oxford BRC was one of 20 successful BRCs throughout England to receive funding for 2017 to 2022 following a competitive bidding process. NIHR BRCs bring together expertise within the NHS and leading research organisations to turn latest discoveries into fundamentally new treatments for patients.

The musculoskeletal theme now in the NIHR Oxford BRC replaces the current NIHR Oxford Musculoskeletal Biomedical Research Unit (BRU), to end in March 2017.

Professor Andrew Carr, Head of Department and theme lead on the new NIHR Oxford BRC, said: 'We are delighted to lead two themes in this successful NIHR Oxford BRC, building on the excellence of translational research of our NIHR Oxford BRU. The close working relationship between basic scientists and clinicians fostered by the BRC partnerships has already led to novel treatments and will continue to allow us to improve the lives of our patients.'

Musculoskeletal Theme

Our vision is to build on our established and proven strengths in the identification of therapeutic targets and to accelerate the translation of new personalized therapies in inflammatory joint disease, degenerative joint disorders and in rare bone diseases. We will also further develop and translate Oxford's promising tissue engineering implants and devices and regenerative medicine therapies for the benefit of patients.

Gastroenterology & Mucosal Immunity Theme

Inflammation underpins many common gastrointestinal tract and liver (GI) and skin diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), non-alcoholic fatty liver disease (NAFLD), psoriasis and atopic dermatitis (AD) that are a significant source of morbidity and mortality. We envisage a new taxonomy of disease, based on molecular pathogenesis, to identify unique and common drivers of disease across GI and skin diseases. This will enable enhanced diagnosis and treatment strategies ensuring expensive immunotherapies with potential side effects are targeted to those patients most likely to benefit.

Similar stories

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Womens Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.